改良脓毒症肾绞痛指数对儿童脓毒性休克严重急性肾损伤预测的外部验证
本研究为前瞻性多中心观察性研究的二次分析,纳入2019年1月至2022年12月入住儿科重症监护室的脓毒性休克患儿363例,第1天计算sRAI(RAI≥20,或RAI 8至<20且血小板<150×10³/µL),主要终点为第3天严重AKI(≥KDIGO 2期)。79例(22%)发生D3严重AKI;sRAI阳性140例(39%),原始RAI阳性195例(54%),D1肌酐高于基线253例(70%)。sRAI阳性者D3严重AKI(RR 8.9)、肾脏替代治疗(RR 18)和死亡(RR 2.5)风险均更高;sRAI预测D3严重AKI的AUROC为0.86,特异度74%,高于D1肌酐高于基线(36%)和原始RAI阳性(58%)。多因素回归中sRAI阳性仍与D3严重AKI(aOR 4.5)和需肾脏替代治疗(aOR 5.6)相关。作者认为sRAI在该人群中较无背景的肌酐升高或原始RAI预测更准确、更特异。
要点
- 363例脓毒性休克患儿中22%(79例)发生第3天严重AKI(≥KDIGO 2期),sRAI阳性者风险为阴性者的8.9倍(RR 8.9,95%CI 5-16,p<0.001)。
- sRAI阳性者肾脏替代治疗风险RR 18(95%CI 6.6-49,p<0.001),死亡风险RR 2.5(95%CI 1.2-5.5,p=0.013)。
- sRAI预测D3严重AKI的AUROC 0.86(95%CI 0.82-0.90),特异度74%,高于D1肌酐高于基线(36%)和原始RAI阳性(58%)。
- 多因素回归中sRAI阳性与D3严重AKI(aOR 4.5,95%CI 2.0-10.2,p<0.001)及需KRT(aOR 5.6,95%CI 1.5-21.5,p=0.01)独立相关。
- sRAI阳性定义:RAI≥20,或RAI 8至<20且血小板<150×10³/µL;原始RAI阳性定义为RAI≥8。
适用人群与场景
- 2019年1月至2022年12月入住儿科重症监护室的脓毒性休克患儿,为前瞻性多中心观察性研究的二次分析人群。
诊断标准与关键阈值
- sRAI阳性(脓毒症肾绞痛达标):RAI≥20,或RAI 8至<20且血小板<150×10³/µL。
- 原始RAI阳性:RAI≥8。
- 严重AKI定义:第3天≥KDIGO 2期。
- D1肌酐高于基线:第1天血清肌酐高于基线。
红旗征与不能漏的情况
- sRAI阳性患儿第3天严重AKI风险升高(RR 8.9,95%CI 5-16,p<0.001),需肾脏替代治疗风险升高(RR 18,95%CI 6.6-49,p<0.001),死亡风险升高(RR 2.5,95%CI 1.2-5.5,p=0.013)。
研究设计与关键结果
- 研究类型:前瞻性多中心观察性研究的二次分析,纳入363例脓毒性休克患儿,79例(22%)发生D3严重AKI。
- sRAI阳性140例(39%),原始RAI阳性195例(54%),D1肌酐高于基线253例(70%)。
- sRAI阳性 vs sRAI阴性:D3严重AKI RR 8.9(95%CI 5-16,p<0.001),KRT RR 18(95%CI 6.6-49,p<0.001),死亡RR 2.5(95%CI 1.2-5.5,p=0.013)。
- sRAI预测D3严重AKI的AUROC 0.86(95%CI 0.82-0.90),特异度74%,高于D1肌酐高于基线(36%)和原始RAI阳性(58%)。
- 多因素回归:sRAI阳性与D3严重AKI相关(aOR 4.5,95%CI 2.0-10.2,p<0.001),与需KRT相关(aOR 5.6,95%CI 1.5-21.5,p=0.01)。
证据类型、等级与局限
- 证据类型:前瞻性多中心观察性研究的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在儿童脓毒性休克中预测严重AKI对改善结局、分配资源和为临床试验入组提供信息很重要;sRAI在该人群中较无背景的肌酐升高或原始RAI预测更准确、更特异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute kidney injury (AKI) occurs commonly in pediatric septic shock and increases morbidity and mortality. Early identification of high-risk patients can facilitate targeted intervention to improve outcomes. We previously modified the renal angina index (RAI), a validated AKI prediction tool, to improve specificity in this population (sRAI). Here, we prospectively assess sRAI performance in a separate cohort.
METHODS: A secondary analysis of a prospective, multicenter, observational study of children with septic shock admitted to the pediatric intensive care unit from 1/2019 to 12/2022. The primary outcome was severe AKI (≥ KDIGO Stage 2) on Day 3 (D3 severe AKI), and we compared predictive performance of the sRAI (calculated on Day 1) to the original RAI and serum creatinine elevation above baseline (D1 SCr > Baseline +). Original renal angina fulfillment (RAI +) was defined as RAI ≥ 8; sepsis renal angina fulfillment (sRAI +) was defined as RAI ≥ 20 or RAI 8 to < 20 with platelets < 150 × 103/µL.
RESULTS: Among 363 patients, 79 (22%) developed D3 severe AKI. One hundred forty (39%) were sRAI + , 195 (54%) RAI + , and 253 (70%) D1 SCr > Baseline + . Compared to sRAI-, sRAI + had higher risk of D3 severe AKI (RR 8.9, 95%CI 5-16, p < 0.001), kidney replacement therapy (KRT) (RR 18, 95%CI 6.6-49, p < 0.001), and mortality (RR 2.5, 95%CI 1.2-5.5, p = 0.013). sRAI predicted D3 severe AKI with an AUROC of 0.86 (95%CI 0.82-0.90), with greater specificity (74%) than D1 SCr > Baseline (36%) and RAI + (58%). On multivariable regression, sRAI + retained associations with D3 severe AKI (aOR 4.5, 95%CI 2.0-10.2, p < 0.001) and need for KRT (aOR 5.6, 95%CI 1.5-21.5, p = 0.01).
CONCLUSIONS: Prediction of severe AKI in pediatric septic shock is important to improve outcomes, allocate resources, and inform enrollment in clinical trials examining potential disease-modifying therapies. The sRAI affords more accurate and specific prediction than context-free SCr elevation or the original RAI in this population.
参考来源
- Stanski NL, Basu RK, Cvijanovich NZ, et al. External validation of the modified sepsis renal angina index for prediction of severe acute kidney injury in children with septic shock. Crit Care. 2023. PMID: 38017578. doi:10.1186/s13054-023-04746-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。